Implementation of quality indicators for ovarian cancer in gynecological cancer centers certified by the German Cancer Society (DKG)
This study demonstrates that German Cancer Society-certified gynecological centers have achieved high and improving adherence to guideline-based quality indicators for ovarian cancer, validating their effectiveness for benchmarking and continuous quality improvement.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Ovarian cancer remains the most deadly of the gynecological cancers, a disease that often reveals itself only after it has spread deep within the body. In Germany, where roughly seven thousand new cases are diagnosed each year, the timing of discovery is a critical factor; most patients are already in advanced stages when they receive a diagnosis. For decades, medical experts have known that the quality of care a patient receives can change the outcome, but measuring that quality has been difficult. To solve this, the German Cancer Society began certifying specialized cancer centers in 2008. This system does not just check if a hospital has the right equipment; it requires these centers to prove they are following the best possible treatment steps, known as guidelines. These guidelines act as a roadmap, telling doctors exactly what to do, from the type of surgery performed to the specific medicines used. To ensure these roadmaps are actually being followed, the society created specific checkpoints called quality indicators. These are simple, countable measures that show whether a center is doing the right things for the right patients, turning complex medical care into clear, comparable facts.
A new study by researchers from several German institutions, including the University Hospital Erlangen and the German Cancer Society, examines how well these checkpoints are working for ovarian cancer. The team looked at data from 184 certified centers that treated nearly five thousand primary ovarian cancer cases in 2024. Their goal was to see if the hospitals were meeting the strict targets set by the national guidelines and to track how these numbers have changed over the last five years. The researchers focused on five key areas of care that they believed made the biggest difference in patient survival: performing a thorough surgical staging for early-stage disease, offering genetic testing to all patients, achieving a complete removal of visible tumors in advanced cases, ensuring that a specialist surgeon performs the operation, and using the correct standard chemotherapy regimen. By analyzing the records from 2019 through 2024, the team could see not just a snapshot of the current situation, but a story of how these centers improved their practices over time.
The results show a system that is working with remarkable consistency. In 2024, almost every single center met the targets for the most critical procedures. For instance, 99.5 percent of the centers successfully achieved the goal of completely removing all visible tumors during surgery for advanced cancer, a result that is vital because leaving even a small amount of tumor behind significantly lowers a patient's chance of survival. Similarly, 98.9 percent of centers ensured that these complex surgeries were performed by a gynecologic oncologist, a specialist specifically trained in this field. The data also revealed a dramatic shift in how genetic testing is handled. In 2019, when the tracking began, only about 61 percent of patients were offered genetic testing, which is crucial for determining if a patient has an inherited risk or if they might respond to newer targeted therapies. By 2024, that number had climbed to 84 percent across all centers, with nearly every center now offering the test to at least 70 percent of their patients. This rise suggests that the requirement to report these numbers has successfully pushed hospitals to adopt better practices.
The study also highlights how the system adapts as medical knowledge grows. The researchers noted that some of the original checkpoints were retired because they were no longer needed; for example, the rule about avoiding chemotherapy in very early, low-risk cases was dropped because every center had already mastered that practice. Instead, the focus shifted to more complex areas where improvement was still possible. The data shows that while the centers are doing exceptionally well, the work is never finished. The researchers observed that the gap between the best-performing centers and the rest has narrowed significantly over the years, suggesting that the certification process helps all hospitals learn from one another. However, the authors are careful to note that while the data proves these centers are following the rules, the study design cannot prove that the certification itself caused the better survival rates seen in other large studies. What the numbers do show is that when hospitals are asked to measure and report their performance against clear, evidence-based standards, they rise to the challenge, turning high-quality care from an ideal into a daily reality for thousands of patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.